Medical World News® After Hours: Oncologist Amy Comander, MD, Discusses Marathon Running and Motivation

Video

During an After Hours segment of Medical World News®, Amy Comander, MD, spoke about her passion for marathon running and how it helps keep her inspired in her work as an oncologist.

A recent ‘Narratives in Oncology’ article written for The Oncologist journal details the experience of physician and marathon runner Amy Comander, MD, with the 124th Boston Marathon. Like most events scheduled in 2020, the marathon was canceled due to the COVID-19 pandemic. In her narrative, Comander discusses gratitude and resilience in times of uncertainty, explaining how the running community has helped her remember to keep her head up.

In addition, Comander has helped organize fundraising races, like the PAVING Program 5K, a virtual 5k to be held June 4 through 6, 2021.

CancerNetwork® sat down with Comander, of the Mass General Cancer Center in Waltham and Harvard Medical School, to talk about what marathon running means to her and her plans for participating in future races.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

References

1. Comander A. Remember Your Why: An Oncologist's Reflections on Running During the COVID-19 Pandemic. Oncologist. 2021;26(4):348-349. doi:10.1002/onco.13683

Recent Videos
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Related Content